Aldevron to generate antibodies for erythropoietin research consortium

(PresseBox) ( Freiburg, )
Aldevron is pleased to announce its participation in a new three year, €3.9 million research project to study the long-term risks of erythropoietin (EPO) and its derivatives (epoetins) in cancer patients. EPO is commonly used to treat anemia related to cancer and cardiovascular surgery. This project funded by the European Union is coordinated by Dr. Drorit Neumann, University of Tel Aviv, and has 13 collaborators throughout Europe and Israel.

Aldevron, a leader in the field of genetic immunisation, will apply its proprietary GENOVAC Antibody Technology to develop sets of monoclonal antibodies against the erythropoietin receptor (EpoR) for different applications, including antibodies capable of detecting EpoRs in its native conformation in tumour samples and the ability to modulate the function of this receptor.

Dr. John Thompson of Aldevron, a pioneer in the genetic immunisation technology to be deployed, noted that GENOVAC Antibody Technology is uniquely suited to provide antibodies to the EPO research consortium and is pleased to produce "antibodies that could further be developed as therapeutic drugs for certain indications."

The research consortia, called EPOCAN, plans to implement a comprehensive interdisciplinary strategy to identify and alleviate the risks involved in treatment with erythropoietin (EPO) and its derivatives (epoetins) in cancer patients and those with chronic kidney disease. It is estimated that up to one million patients across Europe and North America receive epoetin treatment each year.
The publisher indicated in each case is solely responsible for the press releases above, the event or job offer displayed, and the image and sound material used (see company info when clicking on image/message title or company info right column). As a rule, the publisher is also the author of the press releases and the attached image, sound and information material.
The use of information published here for personal information and editorial processing is generally free of charge. Please clarify any copyright issues with the stated publisher before further use. In the event of publication, please send a specimen copy to